DNA delivered by lipid nanoparticles induces CD8+ T cell–dependent antitumor responses and enhances anti–PD-L1 therapy
JCI Insight · 2026
DOI: 10.1172/jci.insight.197404 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Seoyun Yum und 16 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Group, Spark Therapeutics Inc., Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Nanoparticles, Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NA.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have reshaped the treatment landscape of several cancer types. However, their effectiveness remains limited to a subset of patients, in part due to insufficient preexisting antitumor immunity. In this study, we hypothesized that intracellular delivery of noncoding dsDNA encapsulated in lipid nanoparticles (DNA-LNPs), which have recently been demonstrated to activate both STING and absent in melanoma 2 (AIM2) pathways, could enhance antitumor immune responses and potentiate ICI therapy. Using multiple animal models of cancer, including hepatocellular carcinoma, acute myeloid leukemia, melanoma, and melanoma lung metastasis, we show that DNA-LNP treatment triggered strong cytokine induction and robust CD8 + T cell recruitment to the tumor microenvironment. This immune activation mediated potent CD8 + T cell–dependent antitumor effects and prolonged animal survival across multiple models. Notably, empty LNPs did not elicit potent cytokine elevation or antitumor effects, suggesting that these responses are triggered by the activation of cytosolic DNA-sensing pathways. Moreover, DNA-LNPs synergized with anti–PD-L1, substantially extending animal survival in both ICI-responsive and ICI-resistant tumor models. These findings position DNA-LNPs as a promising immunotherapy strategy, either alone or in combination with ICI therapies, to enhance antitumor immunity across diverse cancer types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery Group, Spark Therapeutics Inc., Philadelphia, Pennsylvania, USA.
- Cellular Immunotherapies for Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Förderung
- NA
Zitieren
APA
Yum, S., Rodríguez-Garcia, A., Castellsagué, J., Giménez-Alejandre, M., Colell, G., Colell, S., Lobo-Jarne, T., LaRue, M. A., Minnier, M. A., Yazicioglu, M. N., Zhang, R., Anguela, X. M., Nahvi, A., Walsh, M. C., Armour, S. M., Guedan, S., & Cejas, P. J. (2026). DNA delivered by lipid nanoparticles induces CD8+ T cell–dependent antitumor responses and enhances anti–PD-L1 therapy. JCI Insight. https://doi.org/10.1172/jci.insight.197404
Vancouver
Yum S, Rodríguez-Garcia A, Castellsagué J, Giménez-Alejandre M, Colell G, Colell S, et al. DNA delivered by lipid nanoparticles induces CD8+ T cell–dependent antitumor responses and enhances anti–PD-L1 therapy. JCI Insight. 2026. doi:10.1172/jci.insight.197404
BibTeX
@article{Yum2026,
author = {Yum, Seoyun and Rodríguez-Garcia, Alba and Castellsagué, Joan and Giménez-Alejandre, Marta and Colell, Guillem and Colell, Salut and Lobo-Jarne, Teresa and LaRue, Mark A and Minnier, Michael A and Yazicioglu, Mustafa N and Zhang, Rui and Anguela, Xavier M and Nahvi, Ali and Walsh, Matthew C and Armour, Sean M and Guedan, Sonia and Cejas, Pedro J},
title = {DNA delivered by lipid nanoparticles induces CD8+ T cell–dependent antitumor responses and enhances anti–PD-L1 therapy},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.197404}
}
EUVIMED